Centene cut to Hold at Argus amid Medicare and Medicaid uncertainty

As previously reported, Argus downgraded Centene (CNC) to Hold from Buy. The firm sees potential headwinds for the shares as changing eligibility requirements and uncertainty as to whether Centene will be allowed to offer Medicaid in certain states could restrict the share price, the analyst tells investors in a research note. Growth prospects for the company’s Medicare Advantage business are also unclear, Argus adds, lowering the firm’s FY25 EPS view by 50c to $7.50.